The Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou 225000, Jiangsu, China.
Clinical Medical College, Yangzhou University, Yangzhou 225001, China.
Iran J Immunol. 2023 Dec 31;20(4):466-472. doi: 10.22034/iji.2023.99254.2629. Epub 2023 Oct 24.
Hemophagocytic lymphohistiocytosis (HLH) is a fatal clinical syndrome. The most common cause of secondary HLH is Epstein-Barr virus (EBV) infection. EBV-HLH is a common clinical disease with high mortality, easy relapse, and poor prognosis. Therefore, treating EBV-HLH with T and B lymphocyte involvement is challenging, and selecting an appropriate treatment regimen is critical. Moreover, research on how to evaluate the recurrence index after remission is scarce. In this study, we reported a case of EBV-HLH successfully treated with programmed cell death protein-1 (PD-1) inhibitor in combination with rituximab. The regimen had a good curative effect, and we successfully detected the trend of early recurrence. Our findings indicated that PD-1 inhibitor in combination with rituximab may help to treat EBV-HLH and maintain EBV-infected T and B whole-line lymphocytes.
噬血细胞性淋巴组织细胞增生症（HLH）是一种致命的临床综合征。继发性 HLH 最常见的原因是 EBV 感染。EBV-HLH 是一种常见的临床疾病，死亡率高，易复发，预后差。因此，治疗 EBV-HLH 伴 T、B 淋巴细胞受累具有挑战性，选择合适的治疗方案至关重要。此外，关于如何评估缓解后复发指数的研究较少。本研究报道了 1 例 EBV-HLH 患者成功接受程序性死亡蛋白-1（PD-1）抑制剂联合利妥昔单抗治疗。该方案疗效良好，我们成功地检测到早期复发的趋势。我们的研究结果表明，PD-1 抑制剂联合利妥昔单抗可能有助于治疗 EBV-HLH，并维持 EBV 感染的 T、B 全谱系淋巴细胞。
